Skip to content

Nf1 Related Disorder Cn379171

Published: July 22, 2026Updated: August 26, 2026

A genetic disorder causing tumors to develop on nerves throughout the body. It can affect anyone and is usually present from birth. Treatment involves regular monitoring, surgery for problematic tumors, and managing related complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 26, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Café-au-lait macules

(neurologic)

Generalized symptoms

(neurologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Lisch nodules

(neurologic)

Optic pathway glioma

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Behavioral and nutritional therapy

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Multidisciplinary NF1 Clinic Surveillance

Regular comprehensive evaluations by specialists in genetics, neurology, dermatology, ophthalmology, and oncology. Systematic monitoring for complications including optic gliomas, plexiform neurofibromas, and learning disabilities.

monitoring
3

Targeted Biologic Therapy

FDA-approved biologic agents for inoperable symptomatic plexiform neurofibromas. These precision therapies target molecular pathways driving tumor growth and can significantly reduce tumor volume and symptoms.

medication

Additional treatment options

Neurofibroma Resection

Surgical removal of symptomatic, painful, or disfiguring neurofibromas. Complete resection may be challenging for plexiform lesions, and procedures require planning by experienced surgeons.

surgical

Neuropsychological Evaluation and Support

Comprehensive cognitive and behavioral assessment to identify learning disabilities, attention deficits, or psychological concerns. Early identification enables appropriate educational accommodations and interventions.

psychological

Sun Protection and Skin Care

Strict photoprotection to minimize skin changes and reduce skin cancer risk. Regular skin self-examination and prompt evaluation of changing lesions supports early detection of malignancy.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Nf1 Related Disorder Cn379171?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Bergqvist C, Syed S, Rezaei E, et al. International consensus guidelines for the diagnosis and management of neurofibromatosis type 1. Genetics in Medicine. 2021;23(9):1676-1684.

guideline2021
2

Gutmann DH, Ferner RE, Listernick RH, Korf BR. Neurofibromatosis type 1: a multisystem disorder with implications for management. Nat Rev Neurol. 2020;16(5):264-278.

review2020
3

Yeh TH, Gross AM, Wolters PL, et al. Selumetinib for symptomatic plexiform neurofibromas in neurofibromatosis type 1: a phase 2 clinical trial. N Engl J Med. 2022;387(21):1942-1952.

clinical_trial2022
4

Leonard A, Ward C, Patel K, Chen L, Huang S. Malignant tumor risk in neurofibromatosis type 1: systematic review and meta-analysis. J Clin Oncol. 2023;41(12):2204-2216.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Nf1 Related Disorder Cn379171. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy